Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE PHOSPHATE vs HALOTHANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
Radical cure of relapsing malaria caused by Plasmodium vivax or P. ovale,Prevention of relapse in malaria due to P. vivax or P. ovale,Off-label: Terminal prophylaxis of malaria (after leaving endemic area) to prevent relapse,Combination therapy for treatment of uncomplicated malaria (with clindamycin or other agents)
Induction and maintenance of general anesthesia,Sedation in intensive care (off-label),Status asthmaticus (off-label, due to bronchodilation)
Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
Terminal elimination half-life ranges from 4 to 6 hours in healthy adults; may be prolonged in renal impairment. Clinical context: due to short half-life, daily dosing is required; accumulation of active metabolites may contribute to efficacy.
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
Primaquine is extensively metabolized in the liver, primarily via CYP2C8 and CYP2D6. Major metabolites include carboxyprimaquine and other oxidative products.
Halothane is metabolized in the liver primarily by cytochrome P450 2E1 (CYP2E1) to trifluoroacetic acid and bromide ion; reductive metabolism also produces chloride ions and free radicals.
Renal: approximately 1% unchanged; major metabolites (e.g., carboxyprimaquine) are excreted renally. Fecal/biliary: minor route (less than 5%). Total renal elimination of parent drug and metabolites accounts for about 60-70% of a dose.
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Approximately 70% bound to plasma proteins (primarily albumin).
Approximately 20-30% bound to plasma proteins, primarily albumin and lipoproteins.
2.5-3.5 L/kg; extensive distribution into tissues including liver, lungs, and erythrocytes.
Volume of distribution at steady state (Vdss) approximately 2-5 L/kg; large Vd indicates extensive tissue distribution, especially to adipose tissue, brain, and muscle.
Oral: approximately 75-80% (first-pass metabolism reduces systemic availability; food decreases rate but not extent).
100% bioavailable via inhalation (only route of administration). Oral bioavailability not applicable.
No specific guidelines; use with caution in renal impairment. For severe renal impairment (Cr Cl <30 m L/min), consider alternative therapy due to lack of data.
No specific dose adjustment required for renal impairment; use with caution due to potential nephrotoxicity from fluoride ions.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor for adverse effects; dose adjustment not well defined, but consider reducing dose to 15 mg (base) daily and monitoring G6PD status.
Child-Pugh Class A: no adjustment; Child-Pugh Class B and C: avoid use; contraindicated in patients with hepatic impairment or history of halothane-induced hepatotoxicity.
Children: For radical cure of P. vivax or P. ovale: 0.5 mg/kg (base) orally once daily for 14 days (maximum 30 mg). For prophylaxis: 0.5 mg/kg (base) orally once daily (maximum 30 mg) starting 1 day before travel, daily during travel, and 7 days after leaving endemic area. Must test for G6PD deficiency before use.
Induction: 0.5-2% in oxygen or oxygen-nitrous oxide mixture, gradually increased; Maintenance: 0.3-1.5% as needed. Use lowest effective dose.
No specific dose adjustments; use with caution due to age-related decline in hepatic and renal function. Monitor for hemolytic anemia and gastrointestinal effects. Consider lower starting dose (15 mg base daily) and adjust based on tolerability.
Reduce dose by 25-50% due to increased sensitivity and reduced clearance; monitor hemodynamics closely.
Primaquine phosphate can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency must be ruled out before starting treatment. Severe hemolysis may occur and can lead to death.
Halothane can cause hepatic necrosis, which may be fatal. Fatalities have occurred in patients with previous halothane exposure. Avoid repeat exposure within 3-6 months.
Hemolytic anemia in G6PD-deficient patients: Screen for G6PD deficiency prior to use and avoid in such patients unless benefit outweighs risk,Methemoglobinemia: Can occur, especially in patients with NADH-methemoglobin reductase deficiency or other predisposing conditions,Hematologic toxicity: Monitor blood counts; caution in patients with anemia or other blood disorders,Hepatic impairment: Use with caution; may need dose adjustment,Psychiatric effects: Rarely associated with anxiety, confusion, or psychosis
Hepatotoxicity (halothane hepatitis), malignant hyperthermia, cardiac arrhythmias (sensitizes myocardium to catecholamines), respiratory depression, hypotension, increased intracranial pressure.
G6PD deficiency (absolute contraindication due to risk of hemolytic anemia),Known hypersensitivity to primaquine or other 8-aminoquinolines,Concurrent use with other hemolytic agents or drugs causing methemoglobinemia,Lupus erythematosus (relative contraindication; may exacerbate),Rheumatoid arthritis (relative contraindication; may exacerbate)
Hypersensitivity to halothane, known or suspected susceptibility to malignant hyperthermia, history of unexplained jaundice or fever after halothane, hepatic dysfunction following previous halothane exposure, pregnancy (relative, especially first trimester).
Grapefruit juice may increase plasma concentrations of primaquine, raising risk of toxicity. Take with food to reduce gastrointestinal irritation. No other significant food interactions known.
No specific food interactions. However, fasting is required before anesthesia to reduce aspiration risk. Alcohol should be avoided for at least 24 hours post-anesthesia due to additive CNS depression.
FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk of hemolytic anemia in G6PD-deficient fetuses; use only if clearly needed.
Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated with a potential increased risk of congenital malformations based on limited epidemiological data. Second and third trimester use may cause fetal depression and uterine atony; prolonged exposure can lead to neonatal respiratory depression. Avoid use during pregnancy unless clearly needed.
Excreted into breast milk in small amounts. M/P ratio not established. Use caution; avoid in G6PD-deficient infants. Consider risk of hemolytic anemia.
Halothane is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.4. Due to low oral bioavailability, risks to the nursing infant are minimal. However, caution is advised as effects on the infant have not been fully studied. Consider pumping and discarding milk for 24-48 hours after anesthesia to minimize exposure.
No specific dose adjustments recommended for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may affect efficacy; however, standard dosing is typically used with careful monitoring.
No specific dose adjustment is recommended, but pregnancy alters pharmacokinetics: increased volume of distribution and decreased protein binding may require higher initial doses to achieve desired anesthetic depth. However, due to increased sensitivity to myocardial depression and uterine relaxation, use the minimum effective dose. Reduce concentration as needed to maintain uterine perfusion and avoid fetal hypoxia.
Primaquine is the only 8-aminoquinoline used for radical cure of Plasmodium vivax and P. ovale hypnozoites. Screen for G6PD deficiency before initiation to prevent hemolytic anemia. Administer with food to reduce gastrointestinal upset. Watch for methemoglobinemia; discontinue if cyanosis or oxygen saturation drops. Avoid in pregnancy and lactation unless benefit outweighs risk.
Halothane is a volatile halogenated hydrocarbon anesthetic. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias; avoid epinephrine use. Associated with halothane hepatitis (immune-mediated hepatotoxicity), especially with multiple exposures. Malignant hyperthermia trigger; have dantrolene ready. Use with caution in patients with increased intracranial pressure as it can elevate ICP. Use with low fresh gas flows to minimize pollution and cost.
Take with food or milk to prevent stomach upset.,Complete the full course even if you feel better.,Report dark urine, yellowing of skin/eyes, or unusual tiredness immediately.,Avoid grapefruit juice as it may increase side effects.,Do not use during pregnancy or breastfeeding without consulting your doctor.,Keep out of reach of children and store at room temperature.
This medication will make you unconscious for surgery. You will not feel pain or remember the procedure.,You must fast before anesthesia; do not eat or drink for at least 6-8 hours before surgery.,Tell your anesthesiologist about any liver problems or previous reactions to anesthesia.,Notify your doctor if you have a personal or family history of malignant hyperthermia.,Avoid alcohol for at least 24 hours after anesthesia.,Do not drive or operate machinery for 24 hours after receiving halothane.
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
"Efonidipine, a dihydropyridine calcium channel blocker, inhibits L-type and T-type calcium channels, leading to vasodilation and reduced myocardial contractility. Halothane, a volatile inhalational anesthetic, depresses myocardial function and sensitizes the myocardium to catecholamines, increasing the risk of arrhythmias. Concurrent use can result in additive negative inotropic effects and profound hypotension, potentially leading to cardiovascular collapse."
"Halothane, a volatile anesthetic, can inhibit the cytochrome P450 enzyme CYP2B6, which is primarily responsible for the metabolism of bupropion, an antidepressant and smoking cessation aid. This inhibition leads to decreased clearance of bupropion, resulting in elevated plasma concentrations that increase the risk of dose-dependent adverse effects such as seizures, anxiety, and insomnia. Clinically, patients may exhibit heightened neuropsychiatric toxicity and reduced seizure threshold, particularly during and after halothane anesthesia."
"Halothane, a volatile halogenated anesthetic, inhibits cytochrome P450 (CYP) isoenzymes, particularly CYP2C19, which is crucial for the hepatic bioactivation of clopidogrel to its active metabolite. Concomitant administration can lead to reduced plasma concentrations of the active thiol metabolite of clopidogrel, diminishing its antiplatelet effect and increasing the risk of thrombotic events such as stent thrombosis or myocardial infarction in patients with coronary artery disease. This interaction is especially significant in patients undergoing surgery where halothane is used for anesthesia while clopidogrel is indicated for recent acute coronary syndrome or percutaneous coronary intervention."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE PHOSPHATE vs HALOTHANE, answered by our medical review team.
PRIMAQUINE PHOSPHATE is a Antimalarial that works by Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.. HALOTHANE is a General Anesthetic that works by Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE PHOSPHATE and HALOTHANE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE PHOSPHATE is: Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.. The standard adult dose of HALOTHANE is: Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRIMAQUINE PHOSPHATE and HALOTHANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRIMAQUINE PHOSPHATE is classified as Category D/X. FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk . HALOTHANE is classified as Category C. Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated w. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.